# Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia

> **NCT04602442** · PHASE2 · UNKNOWN · sponsor: **Olga Tyumina** · enrollment: 90 (estimated)

## Conditions studied

- Covid19
- SARS-CoV-2 PNEUMONIA
- COVID-19

## Interventions

- **DRUG:** EXO 1 inhalation
- **DRUG:** EXO 2 inhalation
- **DRUG:** Placebo inhalation

## Key facts

- **NCT ID:** NCT04602442
- **Lead sponsor:** Olga Tyumina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-01
- **Primary completion:** 2021-08-01
- **Final completion:** 2021-12-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2020-10-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04602442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04602442, "Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04602442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*